CONCLUSIONS
Diabetes, diabetes
CARDIOVASCULAR DISEASE, CVD, DIABETES, BLOOD, DIABETES
Previous studies have demonstrated the benefits of BP reduction to <140 mm Hg on lowering the risk of CVD and all‐cause mortality among subjects with or without diabetes.The BPROAD study is designed to answer the question whether there are additional cardiovascular benefits to lower systolic BP to <120 mm Hg compared with systolic BP to <140 mm Hg among patients with diabetes over a follow‐up period of up to 5 years with an estimated 90% statistical power. Together with the SPRINT and ACCORD trials (Table ACCORD BP, SPRINT, and BPROAD trials.Abbreviations: ACCORD, Action to Control Cardiovascular Risk in Diabetes; BP, blood pressure; BPROAD, Blood Pressure Control Target in Diabetes; CVD, cardiovascular disease; SPRINT, Systolic Blood Pressure Intervention Trial.